The Opportunity:
A Canadian medical device company is seeking a strategic partner to accelerate global commercialization of a patented mobility and patient-transfer system used in institutional healthcare settings (hospitals, long-term care homes, rehabilitation centers). The flagship product is a durable medical device that functions as an accessory to a wheelchair, purpose-built for institutional healthcare settings. It addresses a large and growing market driven by aging populations, chronic caregiver and clinical staffing shortages, and a sector-wide push toward fall prevention and safer patient mobility. The device has no direct competitor offering the same combination of benefits, and has shown fast-growing commercial traction since launch, with expansion opportunities across additional care settings, geographies, and complementary product lines.
Key Highlights:
- Firsttomarket design: the only solution combining active walking support and wheelchair transfer in a single mobile platform, with singleclinician operation.
- Defensible IP position: granted utility patents in North America providing protection through 2037. An active international patent application (PCT) preserves rights across 150+ countries, with a filing election deadline in mid2027, creating a timesensitive window for a buyer seeking global rights.
- Clinically validated: multisite clinical trials in partnership with Canadian universities and hospital systems demonstrated meaningful, doubledigit percentage improvements across multiple patient mobility and confidence outcomes.
- Regulatory cleared: Health Canada approved; Class I exempt status under the FDA framework, positioning the product for nearterm US market entry.
- Early commercial traction: strong initial unit sales across multiple Canadian provinces within the first year of commercialization, with several active B2B distributor relationships already in place and approvals with major national healthcare group purchasing organizations.
- Strong unit economics: manufactured under ISO 9001 & GMPcompliant production with a landed cost representing a small fraction of distributor and retail pricing, supporting gross margins in the mid80% range.
- Institutional research validation: engaged in a funded, multisite evaluation study with an institutional healthcare partner, generating clinical and economic evidence to support broader procurement adoption.
- Platform for growth: the core product is designed as an expandable platform, with several accessory addons already identified on the product roadmap.
- Significant nondilutive validation: meaningful competitive awards and research grant funding across numerous programs, reflecting strong thirdparty and institutional credibility.
Deal Structure:
The company is open to a full acquisition, or a standalone IP/licensing arrangement, and is flexible to align with the strategic objectives of the right counterparty.
Next Steps:
Qualified parties who execute a non-disclosure agreement will receive a detailed Confidential Information Memorandum, including company identity, financial detail, patent references, and management background.
